French biotech and Pfizer find positives in data for Lyme disease vaccine candidate; Altimmune's obesity drug shows promise in PhI trial
French biotech Valneva and partner Pfizer continued to reveal positive results from its Phase II trial for its Lyme disease vaccine candidate.
The Phase II study, which enrolled 246 healthy adults between 18-65 in the US, met its primary endpoint last October, demonstrating that the candidate, known as VLA15, was immunogenic across all dose groups tested and elicited high antibody responses one month after the primary vaccination series. Continued evaluation at Month 18 showed that antibody titers declined across all groups, but remained above baseline, confirming the need for a booster.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.